MeiraGTx Announces FDA Breakthrough Therapy Designation for AAV2-hAQP1 for the Treatment of Grade 2 and Grade 3 Radiation-Induced Xerostomia (RIX) and Reports Fourth Quarter and Full Year 2025 Financial and Operational Results
MeiraGTx (MGTX) was upgraded by Zacks Research from "strong sell" to "hold".
ZipBio and MeiraGTx Enter into Exclusive License Agreement to Advance First-in-Class AAV Gene Therapy for Geographic Atrophy
MeiraGTx (NASDAQ:MGTX) was downgraded by analysts at Zacks Research from a "hold" rating to a "strong sell" rating.
Eli Lilly outlays $1.12bn for hearing loss gene therapy partnership [Yahoo! Finance]